TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
AKTS

Aktis Oncology, Inc.

Healthcare · Biotechnology

22.90$ +0.7% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

Aktis Oncology, Inc. (AKTS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 3.4 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement AKTS
Line item Q2 23 Q3 23 Q4 23 Q1 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
8.3 7.0 7.0 7.5 9.0 0.9 1.4 1.6 1.6 1.9 3.2 3.4 10
10 8.1 6.3 7.2 4.7 0.7 0.9
-1.7 -1.1 0.7 0.3 4.3 0.9 1.6 1.9 2.6 2.5 8.5
8.2 10 6.4 6.0 2.7 13 16 19 16 16 20 25 78
8.1 10 9.3 8.9 6.9 3.9 3.3 3.7 3.1 2.5 5.3 6.4 17
16 21 16 16 9.6 17 20 23 20 19 25 31 96
-18 -22 -15 -23 -5.3 -16 -18 -21 -18 -17 -23 -29 -87
0.4 0.5 0.7 0.7 0.7
-18 -20 -16 -23 -6.4 -12 -15 -18 -16 -15 -18 -24 -73
0.0 0.0 0.0 0.0 0.0
-18 -20 -16 -23 -6.4 -12 -15 -18 -16 -15 -18 -24 -73
-14 -19 -12 -19 -4.0 -12 -18 -14 -18 -28 -78

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?